Which oral antiviral is preferred for an adult with confirmed SARS‑CoV‑2 infection within five days of symptom onset and risk factors for progression?

Nirmatrelvir/Ritonavir is the Preferred Oral Antiviral for COVID-19

For adults with confirmed SARS-CoV-2 infection within five days of symptom onset and risk factors for progression, nirmatrelvir/ritonavir (Paxlovid) is the preferred oral antiviral, dosed as 300 mg/100 mg twice daily for 5 days. 1

Why Nirmatrelvir/Ritonavir is Superior

The WHO living guideline explicitly states that nirmatrelvir/ritonavir represents a superior choice to other oral antivirals based on:

• Greater reduction in hospitalization compared to molnupiravir (moderate certainty evidence) 1
• High certainty evidence of important reduction in hospitalization risk across all risk categories 1
• 88% relative risk reduction in severe outcomes (hospitalization and death) versus 30% for molnupiravir 2
• No concerns about long-term safety unlike molnupiravir's genotoxicity risks 1

Dosing and Timing

• Dose: 300 mg nirmatrelvir/100 mg ritonavir orally every 12 hours for 5 days 1
• Timing: Must start within 5 days of symptom onset; earlier is better 1, 3
• Renal adjustment: Reduce to 150 mg/100 mg every 12 hours if eGFR 30-59 mL/min 1

Critical Drug Interaction Warning

Ritonavir causes extensive drug-drug interactions through CYP450 enzyme inhibition. You must check the Liverpool COVID-19 drug interaction tool before prescribing 1. This is the primary limitation of nirmatrelvir/ritonavir and the main reason to consider alternatives.

When to Use Molnupiravir Instead

Molnupiravir (800 mg twice daily for 5 days) is the second-line option when nirmatrelvir/ritonavir has prohibitive drug interactions 1. However, the WHO recommends it only for high-risk patients, not moderate or low-risk patients 1.

Molnupiravir Contraindications:

• Pregnancy or breastfeeding (embryo-fetal toxicity in animals) 1
• Children (affects bone growth in animals) 1
• Men planning conception (use contraception during treatment and 3 months after) 1
• Younger adults not at high risk (unknown long-term genotoxicity risk) 1

The WHO explicitly recommends against molnupiravir in moderate-risk patients due to concerns about toxicity outweighing benefits 1. Molnupiravir is no longer recommended in EU countries due to lack of clear advantage and risk of immune escape variants 3.

Risk Stratification

High-risk factors warranting treatment include:

• Age >65 years
• Immunocompromise (especially B-cell depletion, hematologic malignancies, transplant recipients) 3
• Multiple comorbidities (diabetes, cardiovascular disease, chronic lung disease)
• Unvaccinated status 4

Recent evidence shows nirmatrelvir reduces hospitalization/death even in vaccinated patients with risk factors, though the absolute benefit is smaller 4. However, the most recent 2026 PANORAMIC trial found no benefit in vaccinated higher-risk outpatients (adjusted OR 1.18,95% CI 0.55-2.62) 5, suggesting the benefit may be primarily in unvaccinated or severely immunocompromised populations.

Special Populations

Immunocompromised patients (hematologic malignancies, cellular therapy): Nirmatrelvir/ritonavir remains first-line. For persistent viral replication or treatment failure, consider combination therapy with remdesivir or prolonged courses (10+ days), though this is off-label 3.

Pregnancy: Nirmatrelvir/ritonavir is an option despite uncertainty, as no serious adverse reactions have been reported in WHO Vigibase 1. Molnupiravir is contraindicated 1.

Common Pitfalls

1. Starting too late: Antivirals must begin within 5 days of symptom onset; efficacy drops significantly after this window 1, 3
2. Ignoring drug interactions: Always check interactions before prescribing nirmatrelvir/ritonavir 1
3. Using molnupiravir in pregnancy or young adults: Serious teratogenic and genotoxic concerns 1
4. Treating low-risk patients: WHO strongly recommends against nirmatrelvir/ritonavir in low-risk patients (strong recommendation) 1

Bottom Line Algorithm

1. Confirm COVID-19 within 5 days of symptom onset
2. Assess risk factors for severe disease
3. If high-risk: Check drug interactions → If none, use nirmatrelvir/ritonavir
4. If drug interactions present: Use molnupiravir (only if high-risk and not pregnant/planning conception)
5. If moderate-risk: Consider nirmatrelvir/ritonavir (conditional recommendation) 1; avoid molnupiravir 1
6. If low-risk: Do not treat with antivirals 1